Research analysts covering MMTec.
Recent press releases and 8-K filings for MTC.
MMTEC Announces Nasdaq Decision on Minimum Bid Price Deficiency
MTC
Delisting/Listing Issues
- MMTEC, Inc. received a decision from the Nasdaq Hearings Panel on December 9, 2025, finding the company in compliance with the minimum bid price rule.
- The company had previously faced a delisting determination because its common stock traded below the $1.00 per share requirement for 30 consecutive business days.
- A one-for-eight reverse stock split on December 18, 2024, made MMTEC ineligible for the standard 180-day compliance period.
- The Panel's decision was based on MMTEC's stock maintaining a closing bid price above $1.00 since November 6, 2025, and includes a one-year discretionary monitor from the date of the Decision Letter.
Dec 11, 2025, 1:30 PM
MMTEC Regains Nasdaq Compliance After Bid Price Deficiency
MTC
Delisting/Listing Issues
- MMTEC, Inc. (MTC) received a decision letter from the Nasdaq Hearings Panel on December 9, 2025, confirming its compliance with the $1.00 minimum bid price rule.
- The company had previously faced delisting due to failing the bid price requirement, exacerbated by a one-for-eight reverse stock split on December 18, 2024, which made it ineligible for the standard compliance period.
- The Nasdaq Hearings Panel approved the company's request to be found in compliance and placed it under a one-year discretionary monitor from the date of the Decision Letter.
- MMTEC's stock has maintained a closing bid price above $1.00 since November 6, 2025.
Dec 11, 2025, 1:30 PM
LICT Corporation Reports Third Quarter 2025 Results and Provides 2025 Outlook
MTC
Earnings
Guidance Update
New Projects/Investments
- LICT Corporation reported third-quarter 2025 revenues of $36.1 million, an increase from $33.7 million in the prior-year quarter, and EBITDA grew 11% to $15.2 million. While net income decreased to $3.6 million from $3.8 million in Q3 2024, earnings per share (EPS) increased to $233 from $228, partly due to a lower share count.
- For the nine months ended September 30, 2025, total revenues were $105.1 million, up 4.2% year-over-year, but EBITDA remained flat at $42.5 million. Net income for the period decreased to $10.9 million from $13.6 million in 2024, resulting in EPS of $687.
- The company provided a 2025 outlook, estimating full-year revenues of approximately $142 million, EBITDA of $58 million, and full-year EPS of approximately $930. Fourth-quarter 2025 EPS is expected to be approximately $240.
- LICT is set to benefit from federal tax reform, with an estimated $25 million in cumulative cash tax savings through 2028 due to reinstated 100% bonus depreciation. Additionally, the company is leveraging government programs, including the FCC E-ACAM program which provides $37.2 million annually through 2038, and has been awarded BEAD and ReConnect grants totaling $157.5 million.
- As of September 30, 2025, Net Debt stood at $68.1 million, with a 1.2x trailing 12-month EBITDA leverage ratio. The company also repurchased $8.3 million of its common stock year-to-date.
Dec 9, 2025, 9:23 PM
BiomX Reports Q3 2025 Financial Results and Provides Clinical Program Updates
MTC
Earnings
Guidance Update
New Projects/Investments
- BiomX Inc. reported a net loss of $9.2 million for the third quarter ended September 30, 2025, compared to a net income of $9.6 million for the third quarter of 2024, primarily due to a change in the fair value of warrants.
- As of September 30, 2025, the company's cash balance and restricted cash totaled $8.1 million, which BiomX estimates is sufficient to fund operations into the first quarter of 2026.
- For its BX004 program for cystic fibrosis, the FDA has placed a clinical hold on the Phase 2b study to review data on a third-party nebulizer, though enrollment and dosing continue outside the U.S.; BiomX expects imminent FDA feedback and anticipates topline results from the Phase 2b study in the first quarter of 2026.
- BiomX received positive FDA feedback for BX011, a multi-phage cocktail targeting S. aureus in diabetic foot infections, confirming a clear clinical development pathway and enabling plans for a Phase 2a trial.
Nov 12, 2025, 12:30 PM
MMTEC, Inc. receives Nasdaq delisting determination
MTC
Delisting/Listing Issues
- MMTEC, Inc. (MTC) received a Nasdaq delisting determination letter on October 27, 2025, for failing to meet the $1.00 minimum bid price requirement for 30 consecutive business days.
- Due to a one-for-eight reverse stock split on December 18, 2024, the company is not eligible for the standard 180-day compliance period.
- Trading in MMTEC's securities is scheduled for suspension on November 5, 2025, unless an appeal is requested by November 3, 2025.
- The company is evaluating its options and currently intends to appeal the determination, though there is no assurance of a successful outcome.
Oct 28, 2025, 6:46 PM
MMTEC Receives Nasdaq Delisting Determination
MTC
Delisting/Listing Issues
- MMTEC, Inc. (MTC) received a delisting determination from Nasdaq on October 27, 2025, for failing to meet the $1.00 minimum bid price requirement for 30 consecutive business days.
- Due to a one-for-eight reverse stock split on December 18, 2024, the company is ineligible for the standard 180-calendar day compliance period.
- If an appeal is not requested, trading in MMTEC's securities will be suspended at the opening of business on November 5, 2025.
- The company has until November 3, 2025, to request a hearing to appeal the determination, which would stay the suspension, and intends to appeal.
Oct 28, 2025, 12:00 PM
Ask Fintool AI Agent
Get instant answers from SEC filings, earnings calls & more